Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03636503
Title RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

follicular lymphoma

Therapies

Avelumab + Rituximab + Utomilumab

Avelumab + PF-04518600 + Rituximab

PF-04518600 + Rituximab + Utomilumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.